全文获取类型
收费全文 | 1399篇 |
免费 | 81篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 72篇 |
妇产科学 | 33篇 |
基础医学 | 164篇 |
口腔科学 | 53篇 |
临床医学 | 102篇 |
内科学 | 322篇 |
皮肤病学 | 24篇 |
神经病学 | 51篇 |
特种医学 | 419篇 |
外科学 | 87篇 |
综合类 | 39篇 |
预防医学 | 27篇 |
眼科学 | 8篇 |
药学 | 42篇 |
1篇 | |
肿瘤学 | 32篇 |
出版年
2023年 | 4篇 |
2022年 | 4篇 |
2021年 | 6篇 |
2020年 | 5篇 |
2019年 | 6篇 |
2018年 | 11篇 |
2017年 | 15篇 |
2016年 | 13篇 |
2015年 | 18篇 |
2014年 | 30篇 |
2013年 | 34篇 |
2012年 | 20篇 |
2011年 | 21篇 |
2010年 | 35篇 |
2009年 | 51篇 |
2008年 | 25篇 |
2007年 | 40篇 |
2006年 | 30篇 |
2005年 | 26篇 |
2004年 | 19篇 |
2003年 | 25篇 |
2002年 | 14篇 |
2001年 | 18篇 |
2000年 | 13篇 |
1999年 | 22篇 |
1998年 | 80篇 |
1997年 | 84篇 |
1996年 | 83篇 |
1995年 | 66篇 |
1994年 | 41篇 |
1993年 | 58篇 |
1992年 | 7篇 |
1991年 | 12篇 |
1990年 | 24篇 |
1989年 | 54篇 |
1988年 | 42篇 |
1987年 | 46篇 |
1986年 | 54篇 |
1985年 | 68篇 |
1984年 | 36篇 |
1983年 | 31篇 |
1982年 | 28篇 |
1981年 | 32篇 |
1980年 | 37篇 |
1979年 | 5篇 |
1978年 | 18篇 |
1977年 | 23篇 |
1976年 | 21篇 |
1975年 | 20篇 |
1914年 | 1篇 |
排序方式: 共有1484条查询结果,搜索用时 187 毫秒
991.
W-H Boehncke† RA Brasie‡ J Barker§ S Chimenti¶ E Daudén M de Rie†† L Dubertret‡‡ A Giannetti§§ A Katsambas¶¶ K Kragballe JM Naeyaert††† J-P Ortonne‡‡‡ J Peyrí§§§ JC Prinz¶¶¶ J-H Saurat R Strohal†††† P van de Kerkhof‡‡‡‡ W Sterry§§§§ 《Journal of the European Academy of Dermatology and Venereology》2006,20(8):988-998
BACKGROUND: Psoriasis is a chronic, inflammatory skin disorder that has a significant impact on quality of life and, particularly in moderate to severe cases, adversely affects the patient's overall health and well-being. Biological treatments, such as etanercept, are being widely adopted across Europe for treatment of moderate to severe psoriasis due to favourable safety and efficacy profiles. The increase in usage, combined with a growing body of clinical evidence, has identified a need to clarify the best use of etanercept within its current treatment label. OBJECTIVE: To prepare a series of recommendations agreed by an expert group of dermatologists, relating to the most effective use of etanercept for psoriasis in Europe, within the product license. METHODS: An expert panel of dermatologists from across Europe completed a Delphi survey to address the current use of etanercept in psoriasis in Europe. In June 2005 the results were presented to the expert panel at their nominal group meeting, and a consensus was agreed. RESULTS: It was recommended that, where possible, patients are initiated on the 50 mg twice-weekly (BIW) dose. Etanercept should be given until remission is achieved (maximum 24 weeks) and retreatment should be initiated according to the physician's judgement. Before commencing treatment, contraindications, such as infection or previous malignancy (within 5 years), should be ruled out. CONCLUSIONS: The consensus presented herein provides valuable clarification of use of etanercept according to the label, which may have wider implications relating to the use of all biological therapies in psoriasis. 相似文献
992.
RA Kapur PA McCann PP Sarangi 《Annals of the Royal College of Surgeons of England》2014,96(7):e32-e35
The management of skeletal metastases can be challenging for the orthopaedic surgeon. They represent a significant source of pain and disability for cancer patients, adding to the morbidity of their condition. Treatment is directed at the alleviation of symptoms and the restoration of function. Metastatic involvement of the proximal humerus can be especially debilitating, having the potential to cause severe pain and loss of function. We present a report of three such cases where reverse geometry proximal shoulder replacement was used to provide a pain free functional range of movement in patients with concomitant rotator cuff disease. In all cases, significant symptomatic relief was achieved postoperatively with preservation of upper limb function. No surgical complications were noted. It is our belief that this novel surgical strategy provides a valuable and effective option for the management of proximal humeral metastatic disease in the rotator cuff deficient patient. 相似文献
993.
994.
995.
996.
997.
Therapeutic angiogenesis constitutes an alternative treatment for patients with extensive tissue ischaemia in whom primary vascular reconstruction procedures are not feasible or have previously failed. At present vascular endothelial growth factor (VEGF) has been the most widely used angiogenic factor in experimental and human clinical trials. Early clinical data provide evidence that gene transfer of the VEGF gene can achieve beneficial angiogenesis, with minimal side-effects. Ongoing phase III clinical studies will reveal definitive efficacy. 相似文献
998.
999.
Detection of altered membrane phospholipid asymmetry in subpopulations of human red blood cells using fluorescently labeled annexin V 总被引:20,自引:12,他引:8
The phospholipids of the human red cell are distributed asymmetrically in the bilayer of the red cell membrane. In certain pathologic states, such as sickle cell anemia, phospholipid asymmetry is altered. Although several methods can be used to measure phospholipid organization, small organizational changes have been very difficult to assess. Moreover, these methods fail to identify subpopulations of cells that have lost their normal phospholipid asymmetry. Using fluorescently labeled annexin V in flow cytometry and fluorescent microscopy, we were able to identify and quantify red cells that had lost their phospholipid asymmetry in populations as small as 1 million cells. Moreover, loss of phospholipid organization in subpopulations as small as 0.1% of the total population could be identified, and individual cells could be studied by fluorescent microscopy. An excellent correlation was found between fluorescence-activated cell sorter (FACS) analysis results using annexin V to detect red cells with phosphatidylserine (PS) on their surface and a PS-requiring prothrombinase assay using similar red cells. Cells that bound fluorescein isothiocyanate (FITC)-labeled annexin V could be isolated from the population using magnetic beads covered with an anti-FITC antibody. Evaluation of blood samples from patients with sickle cell anemia under oxygenated conditions demonstrated the presence of subpopulations of cells that had lost phospholipid asymmetry. While only a few red cells were labeled in normal control samples (0.21% +/- 0.12%, n = 8), significantly increased (P < .001) annexin V labeling was observed in samples from patients with sickle cell anemia (2.18% +/- 1.21%, n = 13). We conclude that loss of phospholipid asymmetry may occur in small subpopulations of red cells and that fluorescently labeled annexin V can be used to quantify and isolate these cells. 相似文献
1000.
EF Castillo RM López J Rodríguez-Silverio RA Bobadilla and C Castillo 《Fundamental & clinical pharmacology》1998,12(6):584-589
Summary— The aim of the present study was to assess the role of vascular α1D -adrenoceptors in the sympathetic vasopressor response in vivo. Specifically, we evaluated the effect of a selective α1D -adrenoceptor antagonist, BMY 7378 (8-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-8-azaspiro(4,5)decane-7,9-dione 2HCI), on the vasopressor response induced by preganglionic (T7 -T9 ) sympathetic stimulation in the pithed rat. The vasopressor response was dose-dependently sensitive to inhibition by intravenous BMY 7378 (0.1, 0.31, 1 and 3.1 mg/kg), doses of 1 and 3.1 mg/kg being equally effective. Like BMY 7378, 5-methylurapidil (0.1, 0.31, 1 and 3.1 mg/kg) antagonized the vasopressor response to spinal stimulation; doses of 1 and 3.1 mg/kg were also equally effective. In combination experiments, BMY 7378 (1 mg/kg, iv) and the α1A -adrenoceptor antagonist, 5-methylurapidil (1 mg/kg, iv), showed an additive effect. The present results demonstrate that the α1D -adrenoceptor subtype plays an important role in the pressor response to sympathetic nerve stimulation in the pithed rat, and confirm the participation of the α1A -adrenoceptor subtype in the same response. 相似文献